ELDN vs. REPL, PHAR, SANA, NUVB, AVBP, TRVI, ANAB, IMTX, DAWN, and MRVI
Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Replimune Group (REPL), Pharming Group (PHAR), Sana Biotechnology (SANA), Nuvation Bio (NUVB), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), AnaptysBio (ANAB), Immatics (IMTX), Day One Biopharmaceuticals (DAWN), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.
Eledon Pharmaceuticals vs. Its Competitors
Eledon Pharmaceuticals (NASDAQ:ELDN) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.
Replimune Group is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Eledon Pharmaceuticals currently has a consensus target price of $9.00, indicating a potential upside of 163.16%. Replimune Group has a consensus target price of $20.83, indicating a potential upside of 89.91%. Given Eledon Pharmaceuticals' higher probable upside, research analysts plainly believe Eledon Pharmaceuticals is more favorable than Replimune Group.
In the previous week, Replimune Group had 2 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 4 mentions for Replimune Group and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.94 beat Replimune Group's score of 0.78 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.
Replimune Group's return on equity of -57.98% beat Eledon Pharmaceuticals' return on equity.
56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 12.3% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Eledon Pharmaceuticals has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.
Summary
Eledon Pharmaceuticals and Replimune Group tied by winning 7 of the 14 factors compared between the two stocks.
Get Eledon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eledon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ELDN) was last updated on 7/12/2025 by MarketBeat.com Staff
